Emtricitabine

규격

143491-57-0CAS 번호

604-363-1EC 번호

4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-oneIUPAC 명칭

C8H10FN3O3S화학식

247.25 g/mol분자량

Emtricitabine; 143491-57-0; Coviracil; Emtriva; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 524W91; dOTFC; BW-524W91; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 2-FTC; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-emtricitabine; 2'-Deoxy-5-fluoro-3'-thiacytidine; Emtricitabina; Emtricitabinum; Emtricitabine, (-)-; DTXSID0040129; CHEBI:31536; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; G70B4ETF4S; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one; DTXCID8020129; 524-W-91; ODEFSEY COMPONENT EMTRICITABINE; TRUVADA COMPONENT EMTRICITABINE; EVIPLERA COMPONENT EMTRICITABINE; STRIBILD COMPONENT EMTRICITABINE; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; 5-Fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one; 2(1H)-PYRIMIDINONE, 4-AMINO-5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-; (-)-(2R,5S)-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2-one; 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-(1,3)oxathiolan-5-yl)-1H-pyrimidin-2-one; beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-1,2-dihydropyrimidin-2-one; RefChem:920932; J05AF09; Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-,(2R-cis)-; 604-363-1; (-)-FTC; BW524W91; C8H10FN3O3S; FTC-(-); BW 524W91; MFCD00870151; 4-Amino-5-fluoro-1-((2R,5S)-rel-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; FTC; PSI-5004; Emtricitabine-d2,15N; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; NCGC00164564-01; 2(1H)-Pyrimidinone,4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-; PSI 5004; Ftc, dl-; Coviracil(TM); DRG-0208; rel-4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Emtriva(TM); Emtricitabine (1.0 mg/mL in Methanol); SMR002533604; BW 1592; 2',3',5-FTC; Emtricitabine, (+/-)-; HSDB 7337; FTC, (-)-; 145213-48-5; UNII-G70B4ETF4S; Emtricitabine [USAN:INN]; (-)-.beta.-L-FTC; UNII-ULS8902U4O; Emtricitabine?; (+/-)-FTC; BW1592; Emtricitabine RS; cis-FTC; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel-; Emtricitabine (Emtriva); Emtricitabine (Standard); Emtricitabine Diastereomer; EMTRICITABINE [MI]; CHEMBL885; Epitope ID:231723; EMTRICITABINE [INN]; EMTRICITABINE [JAN]; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-; EMTRICITABINE [HSDB]; EMTRICITABINE [USAN]; SCHEMBL39708; EMTRICITABINE [VANDF]; MLS003882429; MLS006011556; MLS006011987; EMTRICITABINE [MART.]; EMTRICITABINE [USP-RS]; EMTRICITABINE [WHO-DD]; EMTRICITABINE [WHO-IP]; orb1300973; EMTRICITABINE [EMA EPAR]; GTPL11244; EX-A150; Emtricitabine - Bio-X trade mark; GLXC-05125; HMS2089I05; HMS3713L12; EMTRICITABINE [ORANGE BOOK]; ALBB-038595; MSK10871; Tox21_112193; ((-))-FTC; BDBM50107843; CS1125; EBC-07648; FTC-((-)); HY-17427R; NSC804863; s1704; ATRIPLA COMPONENT EMTRICITABINE; DESCOVY COMPONENT EMTRICITABINE; Emtricitabine (1 mg/mL in Methanol); EMTRICITABINUM [WHO-IP LATIN]; AKOS015853098; AKOS015894950; CCG-220615; CS-1370; DB00879; NC05645; NSC-804863; NCGC00164564-06; NCGC00164564-09; NCGC00164564-10; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-; AS-14099; BE165946; FR157072; HY-17427; NE153331; SY109006; Emtricitabine 100 |Ig/mL in Acetonitrile; CAS-143491-57-0; E1007; E5178; Emtricitabine 100 microg/mL in Acetonitrile; NS00000522; SW220172-1; T6214; D01199; D72669; EN300-119501; M06302; AB01275429-01; F222572; Q422604; BRD-K61452026-001-04-6; 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE, DL-; Z1521553474; Emtricitabine Working Standard (Secondary Reference Standard); .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-5-fluoro-1-[(2R,5S)-2-hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(1H-pyrimidinone; 5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE (2R,5S); 4-?Amino-?5-?fluoro-?1-?[(2R,?5S)?-?2-?(hydroxymethyl)?-?1,?3-?oxathiolan-?5-?yl]?-?,rel-2(1H)-pyrimidinone동의어